Atrium Therapeutics reported a net loss of $41.1 million for the nine months ended September 30, 2026, compared to $20.4 million in the prior year period, driven by a significant increase in general and administrative expenses following its spin-off. The company ended the quarter with $232.1 million in cash, cash equivalents, and short-term investments, bolstered by a $313.4 million transfer from its former parent company.
Atrium Therapeutics reported third quarter 2026 financial results, highlighting the dosing of the first patient in its Phase 1/2 clinical trial for ATR 1072. The company also closed a $50 million private placement, extending its cash runway through 2028 with a pro-forma cash balance of $293.6 million.
Term
Q3 2026
“The last eight months have marked many firsts for Atrium, building toward our transition to a clinical stage company with the initiation of Corventis, the first clinical trial ever to target the root cause of PRKAG2 syndrome.”
Kathleen Gallagher, President and Chief Executive Officer of Atrium Therapeutics
“Our $50 million private placement with leading institutional investors extends our cash runway through 2028. With ~$290 million on our balance sheet, we are well positioned to deliver on our upcoming milestones.”
Brendan Winslow, Chief Financial Officer of Atrium Therapeutics
Atrium Therapeutics announced nonclinical data for its lead therapy ATR 1072 showing reversal of cardiac glycogen accumulation and improvement in hypertrophy in a mouse model of PRKAG2 syndrome. The company plans to present these findings at the American Heart Association Scientific Sessions 2026 and expects initial Phase 1/2 clinical proof-of-concept data in the second half of 2027.
Atrium Therapeutics announced the first patient has been dosed in its Phase 1/2 Corventis clinical trial evaluating ATR 1072 for the treatment of PRKAG2 syndrome. This represents the first interventional clinical trial for this rare genetic cardiomyopathy, with initial proof-of-concept data expected in the second half of 2027.
Atrium Therapeutics filed an amendment to correct the post-offering share count following a PIPE transaction involving 5,170,384 shares of common stock and pre-funded warrants for 1,134,930 shares. The company expects to have 21,571,507 shares outstanding after the closing of the offering and the settlement of spin-off related equity awards.
Atrium Therapeutics entered into a securities purchase agreement for a $50 million private placement (PIPE) involving the sale of 5,170,384 common shares and pre-funded warrants for 1,134,930 shares. The offering was priced at $7.93 per share and included participation from several institutional investors. Proceeds will be used to fund the development of lead product candidates and extend the company's cash runway through 2028.
Value
$50M
Counterparty
Sirenia Capital Management LP, Aberdeen Investments, Montanova, Sessa Capital, Casdin Capital